V A Alabaster

983 total citations
24 papers, 749 citations indexed

About

V A Alabaster is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience and Physiology. According to data from OpenAlex, V A Alabaster has authored 24 papers receiving a total of 749 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 11 papers in Cellular and Molecular Neuroscience and 8 papers in Physiology. Recurrent topics in V A Alabaster's work include Receptor Mechanisms and Signaling (8 papers), Neuropeptides and Animal Physiology (7 papers) and Nitric Oxide and Endothelin Effects (4 papers). V A Alabaster is often cited by papers focused on Receptor Mechanisms and Signaling (8 papers), Neuropeptides and Animal Physiology (7 papers) and Nitric Oxide and Endothelin Effects (4 papers). V A Alabaster collaborates with scholars based in United Kingdom and United States. V A Alabaster's co-authors include Y.S. Bakhle, John R. Vane, S. H. Ferreira, Lewis Joel Greene, Christopher J. Peters, M. K. Davey, Paul R. Gater, Beverley A. Moore, Simon F. Campbell and John C. Danilewicz and has published in prestigious journals such as Nature, Journal of Medicinal Chemistry and The Journal of Urology.

In The Last Decade

V A Alabaster

24 papers receiving 655 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
V A Alabaster United Kingdom	15	379	197	172	106	80	24	749
I.F. Skidmore United Kingdom	16	308 0.8×	88 0.4×	341 2.0×	179 1.7×	64 0.8×	37	870
B S Tsai United States	19	565 1.5×	345 1.8×	377 2.2×	186 1.8×	92 1.1×	37	1.1k
L. B. Jellett Australia	10	343 0.9×	230 1.2×	183 1.1×	56 0.5×	86 1.1×	22	723
Wesley L. Terasaki United States	9	684 1.8×	173 0.9×	201 1.2×	72 0.7×	100 1.3×	10	906
B Berthon France	23	964 2.5×	356 1.8×	265 1.5×	83 0.8×	53 0.7×	39	1.7k
Karl H. Sanders Germany	11	335 0.9×	117 0.6×	63 0.4×	74 0.7×	65 0.8×	20	806
Michael A. Trevethick United Kingdom	19	376 1.0×	242 1.2×	359 2.1×	377 3.6×	76 0.9×	36	1.2k
Jerome H. Fleisch United States	18	448 1.2×	231 1.2×	520 3.0×	141 1.3×	164 2.0×	51	1.2k
Susumu Otomo Japan	14	356 0.9×	207 1.1×	88 0.5×	66 0.6×	33 0.4×	73	657
Kazuo Nunoki Japan	14	508 1.3×	188 1.0×	79 0.5×	49 0.5×	166 2.1×	37	860

Countries citing papers authored by V A Alabaster

Since Specialization

Citations

This map shows the geographic impact of V A Alabaster's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by V A Alabaster with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites V A Alabaster more than expected).

Fields of papers citing papers by V A Alabaster

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by V A Alabaster. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by V A Alabaster. The network helps show where V A Alabaster may publish in the future.

Co-authorship network of co-authors of V A Alabaster

This figure shows the co-authorship network connecting the top 25 collaborators of V A Alabaster. A scholar is included among the top collaborators of V A Alabaster based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with V A Alabaster. V A Alabaster is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Alabaster, V A. (2002). The fall and rise of in vivo pharmacology. Trends in Pharmacological Sciences. 23(1). 13–18. 37 indexed citations

Alabaster, V A. (1998). Discovery and Development of Selective M3 Antagonists for Clinical Use. The Journal of Urology. 2261–2262. 1 indexed citations

Alabaster, V A. (1998). Discovery and Development of Selective M3 Antagonists for Clinical Use. The Journal of Urology. 159(6). 2261–2262. 23 indexed citations

Alabaster, V A. (1997). Discovery & development of selective M3 antagonists for clinical use. Life Sciences. 60(13-14). 1053–1060. 98 indexed citations

Alabaster, V A & Beverley A. Moore. (1993). New perspectives on basic mechanisms in lung disease. 3. Drug intervention in asthma: present and future.. Thorax. 48(2). 176–182. 10 indexed citations

Gater, Paul R., et al.. (1989). A study of the muscarinic receptor subtype mediating mucus secretion in the cat trachea in vitro. Pulmonary Pharmacology. 2(2). 87–92. 18 indexed citations

Alabaster, V A, et al.. (1987). 2,4-Diamino-6,7-dimethoxyquinazolines. 2. 2-(4-Carbamoylpiperidino) derivatives as .alpha.1-adrenoceptor antagonists and antihypertensive agents. Journal of Medicinal Chemistry. 30(6). 999–1003. 21 indexed citations

Alabaster, V A, et al.. (1986). Comparison of potency of α₂‐adrenoceptor antagonistsin vitro: evidence for heterogeneity of α₂‐adrenoceptors. British Journal of Pharmacology. 88(3). 607–614. 44 indexed citations

Alabaster, V A, et al.. (1985). Lack of differential inhibition by nifedipine of pressor responses induced by α1- and α2-adrenoceptor agonists and by angiotensin II in anaesthetized cats. Clinical Science. 68(s10). 73s–75s. 2 indexed citations

10.

Alabaster, V A & M. K. Davey. (1984). Precapillary Vessels. Journal of Cardiovascular Pharmacology. 6. S365–S376. 21 indexed citations

11.

Alabaster, V A. (1980). METABOLISM OF ARACHIDONIC ACID AND ITS ENDOPEROXIDE (PGH₂) TO MYOTROPIC PRODUCTS IN GUINEA‐PIG AND RABBIT ISOLATED LUNGS. British Journal of Pharmacology. 69(3). 479–489. 6 indexed citations

12.

Alabaster, V A, et al.. (1978). Detection and bioassay of pharmacologically active substances released by arachidonic acid from guinea-pig perfused lungs. Journal of Pharmacological Methods. 1(4). 341–350. 11 indexed citations

13.

Alabaster, V A & Y.S. Bakhle. (1976). Release od smooth muscle-contracting substances from isolated perfused lungs. European Journal of Pharmacology. 35(2). 349–360. 19 indexed citations

14.

Alabaster, V A, et al.. (1974). Sites of uptake of3H-5-hydroxytryptamine in rat isolated lung. Histochemistry and Cell Biology. 39(1). 83–91. 34 indexed citations

15.

Alabaster, V A & Y.S. Bakhle. (1973). The removal of noradrenaline in the pulmonary circulation of rat isolated lungs. British Journal of Pharmacology. 47(2). 325–331. 30 indexed citations

16.

Alabaster, V A & Y.S. Bakhle. (1973). The bradykininase activities of extracts of dog lung. British Journal of Pharmacology. 47(4). 799–807. 14 indexed citations

17.

Alabaster, V A & Y.S. Bakhle. (1972). The inactivation of bradykinin in the pulmonary circulation of isolated lungs. British Journal of Pharmacology. 45(2). 299–310. 25 indexed citations

18.

Alabaster, V A & Y.S. Bakhle. (1970). Removal of 5‐hydroxytryptamine in the pulmonary circulation of rat isolated lungs. British Journal of Pharmacology. 40(3). 468–482. 125 indexed citations

19.

Alabaster, V A & Y.S. Bakhle. (1970). Removal of 5-hydroxytryptamine by rat isolated lung.. PubMed. 38(2). 440P–441P. 12 indexed citations

20.

Ferreira, S. H., Lewis Joel Greene, V A Alabaster, Y.S. Bakhle, & John R. Vane. (1970). Activity of Various Fractions of Bradykinin Potentiating Factor against Angiotensin I Converting Enzyme. Nature. 225(5230). 379–380. 135 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact